Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies
Chrysoula G. Gialouri, Savvina Moustafa, Κonstantinos Thomas, et al.
Rheumatology International (2023) Vol. 43, Iss. 3, pp. 421-435
Open Access | Times Cited: 19

Showing 19 citing articles:

Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis
Qingling Xu, Liyuan He, Yufeng Yin
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 32
Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 8, pp. 1983-2038
Open Access | Times Cited: 8
Cardiovascular, cancer, and infection risks of Janus kinase inhibitors in rheumatoid arthritis and ulcerative colitis: A nationwide cohort study
Yongtai Cho, Dongwon Yoon, Farzin Khosrow‐Khavar, et al.
Journal of Internal Medicine (2025)
Open Access
An update ont the safety of biologic therapies for the treatment of polyarticular juvenile idiopathic arthritis
A. Zimmer, Gerd Horneff
Expert Opinion on Drug Safety (2025)
Closed Access
A narrative literature review of the incidence and prevalence of safety outcomes in patients with ulcerative colitis
Milena Gianfrancesco, Abiola O. Awofeso, Diogo Branquinho, et al.
Expert Review of Gastroenterology & Hepatology (2025)
Open Access
Time to talk to adults with rheumatic diseases about herpes zoster vaccination
M.P.B.I. Pier, Gertjan Wolbink, Laura Boekel
The Lancet Rheumatology (2024) Vol. 6, Iss. 4, pp. e247-e251
Closed Access | Times Cited: 3
Exploring the Link between Varicella-Zoster Virus, Autoimmune Diseases, and the Role of Recombinant Zoster Vaccine
Ryuhei Ishihara, Ryu Watanabe, Mayu Shiomi, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 739-739
Open Access | Times Cited: 3
Preventing herpes zoster in immunocompromised patients: Current concepts
Cassandra Calabrese, E. Kirchner, James Fernandez, et al.
Cleveland Clinic Journal of Medicine (2024) Vol. 91, Iss. 7, pp. 437-445
Open Access | Times Cited: 3
Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study
Po‐Ku Chen, Shih‐Hsin Chang, Yi‐Ming Chen, et al.
Clinical Rheumatology (2024) Vol. 43, Iss. 8, pp. 2503-2511
Closed Access | Times Cited: 3
The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases
Jasvinder A. Singh
BioDrugs (2023) Vol. 37, Iss. 5, pp. 625-635
Closed Access | Times Cited: 7
Impact of age and cardiovascular risk factors on the incidence of adverse events in patients with rheumatoid arthritis treated with Janus Kinase inhibitors: data from a real-life multicentric cohort
Stefano Gentileschi, Carla Gaggiano, Arianna Damiani, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Upadacitinib is associated with clinical response and steroid‐free remission for children and adolescents with inflammatory bowel disease
Joseph Runde, Kelsey Ryan, Joseph B. Hirst, et al.
Journal of Pediatric Gastroenterology and Nutrition (2024)
Closed Access | Times Cited: 2
Late-Onset Psoriatic Arthritis: Are There Any Distinct Characteristics? A Retrospective Cohort Data Analysis
Chrysoula G. Gialouri, Gerasimos Evangelatos, Alexios Iliopoulos, et al.
Life (2023) Vol. 13, Iss. 3, pp. 792-792
Open Access | Times Cited: 6
Refractory alopecia in lupus treated with tofacitinib — a case-based review
Rajdeep Sarkar, Prakashini MV, Naga Hinduja, et al.
Clinical Rheumatology (2023) Vol. 42, Iss. 8, pp. 2237-2241
Closed Access | Times Cited: 4
Progress of Tofacitinib in the Treatment of Ankylosing Spondylitis
逸冰 杨
Advances in Clinical Medicine (2024) Vol. 14, Iss. 05, pp. 2221-2228
Closed Access
Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease—time for universal recommendation?
Fabio Salvatore Macaluso, Ambrogio Orlando
Alimentary Pharmacology & Therapeutics (2023) Vol. 57, Iss. 11, pp. 1343-1344
Open Access | Times Cited: 1
Do Tofacitinib Generics Exhibit Conventional Synthetic Disease-Modifying Anti-rheumatic Drug and Non-steroidal Anti-inflammatory Drug-Sparing Ability in the Management of Axial Spondyloarthritis?
Arvind Ganapati, Suvrat Arya, Nïkhil Gupta, et al.
Cureus (2023)
Open Access | Times Cited: 1
Selective JAK-Inhibitors in Spondyloarthritis
Konstantinos D Vassilakis, Konstantina Magiouf, Stefan Siebert, et al.
Mediterranean Journal of Rheumatology (2024) Vol. 35, Iss. Suppl 1, pp. 27-27
Open Access
Vaccination against Herpes zoster in patients with immune-mediated inflammatory rheumatic diseases: new data
N. V. Muravyova, Б. С. Белов
Modern Rheumatology Journal (2024) Vol. 18, Iss. 4, pp. 115-120
Open Access
Page 1

Scroll to top